Nipaxon (Noscapine)

Noscapine, the active ingredient in Nipaxon, is an antitussive presented as an oral formulation for oral use. It acts as a central cough suppressant, targeting the medullary cough centre, and is employed to relieve dry, non‑productive cough in adults and children when other measures are insufficient.

GNH USA supplies Nipaxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across EU‑origin batches. Our distribution network adheres to stringent quality‑assurance protocols and provides reliable logistics for global healthcare providers.

Noscapine acts as a central antitussive to alleviate dry cough and related respiratory irritation.

Dry cough: reduces frequency and intensity of non‑productive cough. Cough due to upper respiratory infection: provides symptomatic relief of throat irritation. Cough associated with bronchitis: helps lessen coughing episodes. Cough in asthma (non‑productive): assists in controlling cough episodes. Post‑operative cough: helps reduce coughing after surgical procedures.

Noscapine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Dizziness - Drowsiness - Headache - Mild skin rash - Gastrointestinal discomfort

Serious or Rare Side Effects: - Allergic reactions, including anaphylaxis - Severe cutaneous reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or elevated liver enzymes - Hematologic abnormalities (e.g., thrombocytopenia) - Seizures (rare)

When prescribing or dispensing Nipaxon, consider the following precautions to ensure safe use.

Dose adjustment: assess hepatic and renal function before initiating therapy. Allergy assessment: avoid in patients with known hypersensitivity to noscapine. Concurrent CNS depressants: use with caution to prevent excessive sedation. Pregnancy and lactation: evaluate risk‑benefit ratio before use. Driving and machinery: caution if dizziness occurs. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Noscapine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Other central cough suppressants (e.g., codeine): additive risk of respiratory depression. - Opioid analgesics: increased central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase noscapine plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Alcohol: can enhance drowsiness and dizziness.